Drug Trial Radar · NCT02883543
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Last checked: Nov 19, 2026Latest source record: Aug 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
330
Planned (sponsor's estimate)
Start
Jun 2016
Primary completion
Jun 2018
Study completion Jun 2019
Sponsor
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent radiotherapy, or icotinib monotherapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
icotinibDrug
Icotinib is orally administered three times per day.
ChemotherapyDrug
Chemotherapy is given by intravenous administration. Three regimens are available in this study. Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2. Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2. Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2
RadiotherapyRadiation
5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: 2 years
- Incidence of radiation injure of the lungsTime frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.